Respiro is developing a non-invasive liquid biopsy platform that uses exhaled breath to detect lung cancer and other respiratory diseases.
Respiro Diagnostics has raised €1.2M across 1 funding round from 7 investors, most recently a Pre-Seed round in Jul 2026. Based in London, UK; active in Healthtech. Data as of 8 Jul 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-07-08 | Pre-Seed | €1.2M |
| Amadeus Capital Partners,Conception X Angel Syndicate,Innovate UK,KQ Labs,SFC Capital,strategic angel investors+1 more |
| View deal → |
